Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.

Authors: Shannon Neville Westin, Kathleen N. Moore, Michael Guy, Scott Jordan, Michael McHale, Eirwen Miller, Sobia Ozair, Kimberly Erin Resnick, Molnár Szabolcs, Flora Zagouri, Pauline Wimberger, Lubomir Bodnar, Shoji Kamiura, Wang Wuliang, Conor Donnelly, Xiaochun Liu, Ross Stewart, Ying Wang, Sonia Iyer, Els Van Nieuwenhuysen

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.5512

Source: Full article

---

Abstract

5512